Vornorexant
![]() | |
Clinical data | |
---|---|
Other names | ORN-0829; TS-142 |
Drug class | Orexin antagonist |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
Chemical and physical data | |
Formula | C23H22FN7O2 |
Molar mass | 447.474 g·mol−1 |
3D model (JSmol) | |
| |
|
Vornorexant (developmental code names ORN-0829, TS-142) is an orexin receptor antagonist which is under development for the treatment of insomnia and sleep apnea syndrome.[1][2][3] It is a dual orexin OX1 and OX2 receptor antagonist (DORA).[1][3] Vornorexant is predicted to have a short elimination half-life in humans,[3] but few clinical data are available so far.[2] As of June 2021, vornorexant is in phase 2 clinical trials for insomnia and phase 1 trials for sleep apnea syndrome.[1]
See also[]
- List of investigational sleep drugs § Orexin receptor antagonists
References[]
- ^ a b c "TS 142 - AdisInsight".
- ^ a b Muehlan C, Vaillant C, Zenklusen I, Kraehenbuehl S, Dingemanse J (November 2020). "Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders". Expert Opin Drug Metab Toxicol. 16 (11): 1063–1078. doi:10.1080/17425255.2020.1817380. PMID 32901578. S2CID 221572078.
- ^ a b c Futamura A, Suzuki R, Tamura Y, Kawamoto H, Ohmichi M, Hino N, Tokumaru Y, Kirinuki S, Hiyoshi T, Aoki T, Kambe D, Nozawa D (July 2020). "Discovery of ORN0829, a potent dual orexin 1/2 receptor antagonist for the treatment of insomnia". Bioorg Med Chem. 28 (13): 115489. doi:10.1016/j.bmc.2020.115489. PMID 32482533. S2CID 216517776.
External links[]
Categories:
- Experimental drugs
- Fluoroarenes
- Hypnotics
- Ketones
- Orexin antagonists
- Oxazines
- Pyrazoles
- Pyridines
- Triazoles
- Nervous system drug stubs